RXRX vs. RLAY: Which Precision Biotech Stock is a Better Bet Now?

Key Takeaways RXRX has shifted focus to REC-4881 and cancer candidates after discontinuing three key programs.RXRX reported $15M in Q1 revenues and holds $509M in cash, funding ops into mid-2027.RLAY narrowed its pipeline, cut costs and lost a Roche partnership, limiting near-term revenue streams.Recursion Pharmaceuticals (RXRX) and Relay Therapeutics (RLAY) are pioneering the use of artificial intelligence (AI) in drug discovery for various indications across different disease areas. They leverage machine ...